Big Money Sentiment decreased to 1.37 in Q4 2018. It has change of 2.74, from 2018Q3’s 4.11. The ratio dived due to Veracyte, Inc. positioning: 7 sold and 39 reduced. 28 funds amassed positions and 35 increased positions. Investors holded 54.00 million in 2018Q3 but now own 27.61 million shares or 48.87% less.
Tci Wealth Advisors invested 0% in Veracyte, Inc. (NASDAQ:VCYT). Neuberger Berman Group Ltd Liability Corporation reported 42,634 shs. Daiwa Group Inc has invested 0% in Veracyte, Inc. (NASDAQ:VCYT). Ameriprise Inc reported 94,980 shs. Jpmorgan Chase owns 76,652 shs. Acadian Asset Limited Liability Company accumulated 313,225 shs. The New York-based Sg Americas Secs Limited has invested 0.02% in Veracyte, Inc. (NASDAQ:VCYT). D E Shaw & Com holds 0% or 178,517 shs. Us Bankshares De, Minnesota-based fund reported 455 shs. State Of Wisconsin Invest Board has 29,300 shs for 0% of their capital. Fincl Bank Of America Corp De owns 139,118 shs or 0% of their US capital. Federated Investors Inc Pa holds 0% of its capital in Veracyte, Inc. (NASDAQ:VCYT) for 1,506 shs. Metropolitan Life Ins Co New York reported 10,544 shs or 0% of all its holdings. Panagora Asset stated it has 150,914 shs. Jane Street Grp Inc Ltd Liability Com reported 0% in Veracyte, Inc. (NASDAQ:VCYT).

Veracyte, Inc. had 6 insider sales and 0 insider buys since October 31, 2018. This’s net activity of $3.01 million. Anderson Bonnie H also sold $145,364 worth of Veracyte, Inc. (NASDAQ:VCYT) shs. On Wednesday, October 31 $540,271 worth of Veracyte, Inc. (NASDAQ:VCYT) was sold by Hall Christopher M.

Earnings report for Veracyte, Inc. (NASDAQ:VCYT) is awaited on May, 7., according to Zacks. The EPS diference is $0.16 or 59.26 % up from last years number. Previous year: $-0.27; Analysts forcast: $-0.11. 37.50 % negative EPS growth is what analysts predict. $-0.08 EPS was reported for last quarter. VCYT hit $25.65 during the last trading session after $0.41 change.Veracyte, Inc. has volume of 552,675 shares. Since April 15, 2018 VCYT has risen 249.41% and is uptrending. VCYT outperformed the S&P 500 by 245.04%.

Veracyte, Inc. (NASDAQ:VCYT) Ratings Coverage

Total analysts of 2 have positions in Veracyte (NASDAQ:VCYT) as follows: 1 rated it a “Buy”, 0 with “Sell” and 1 with “Hold”. The positive are 50%. Since November 29, 2018 according to StockzIntelligence Inc Veracyte has 3 analyst reports. On Tuesday, February 26 BTIG Research maintained Veracyte, Inc. (NASDAQ:VCYT) rating. BTIG Research has “Buy” rating and $23 target. On Thursday, November 29 the rating was downgraded by Janney Capital to “Neutral”.

Veracyte, Inc. operates as a molecular diagnostics firm in the United States.The firm is worth $1.05 billion. The firm uses genomic technology to resolve diagnostic ambiguity.Currently it has negative earnings. It offers Afirma Thyroid FNA Analysis solution for use in thyroid cancer diagnosis; cytopathology testing services; and the Afirma Malignancy Classifiers to manage thyroid nodule patients.

For more Veracyte, Inc. (NASDAQ:VCYT) news announced briefly go to: Nasdaq.com, Businesswire.com, Globenewswire.com, Benzinga.com or Benzinga.com. The titles are as follows: “8 Genomic Testing Stocks That Can Ease the Sting of Theranos – Nasdaq” announced on March 27, 2019, “Veracyte Announces Sponsorship of the Climb to Fight Cancer’s Team Kilimanjaro Expedition – Business Wire” on March 19, 2019, “Research Report Identifies Alamos Gold, Thermo Fisher Scientific, Veracyte, Air Lease, Carlisle Companies, and Medidata Solutions with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement – GlobeNewswire” with a publish date: March 27, 2019, “Daily Biotech Pulse: Immutep Gets US Patent, Conatus NASH Disappointment, Eisai Moves On After Aducanumab Setback – Benzinga” and the last “Daily Biotech Pulse: Biogen Plummets, FDA Greenlights Sleep Disorder Drug, Cellular Biomedicine Offering – Benzinga” with publication date: March 21, 2019.